PLGA-MEDIATED TARGETED DRUG DELIVERY SYSTEM FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
Atherosclerosis is a long-term inflammatory condition that builds up inflammatory cells and fat in artery walls, which can cause serious cardiovascular problems. Current therapeutics focuses exclusively on certain components of the condition, such as inflammation or cholesterol, they frequently fall short of addressing the disease's complex nature. Our novel approach addresses cholesterol build up, oxidative stress, and inflammation all at once with a multi-layered medication delivery device. By targeting many pathogenic processes of atherosclerosis and avoiding the negative effects associated with synthetic medicines, this holistic strategy offers improved patient outcomes.
Biotechnology And National Health
Technologies for human health
From the start of research and development to the point of market readiness, the expected time needed to execute our novel medication delivery system is five to seven years. This timetable includes important phases including preclinical research, clinical
Our approach is intended for worldwide use, with an initial emphasis on areas like North America, Europe, and Asia that have high rates of cardiovascular disease. These regions have sophisticated healthcare systems and strong demand for cutting-edge medical services, making them important marketplaces. The implementation will start in large cities with well-established healthcare facilities so that distribution and monitoring can be done effectively. Forming alliances with nearby medical facilities and providers will make it easier for new patients to accept and incorporate established treatment plans.
Our multi-layered drug delivery technology offers significant advantages over existing atherosclerosis treatments because it incorporates natural components from Calotropis gigantea and Prosopis juliflora. In contrast to conventional treatments like PCSK9 inhibitors and statins , which mainly target cholesterol reduction, our approach targets arterial plaque inflammation, oxidative stress, and accumulation of cholesterol at the same time. Moreover, our methodology presents unique advantages over antiplatelet agents and anti-inflammatory medications , which fails to fully address the complex pathophysiology of atherosclerosis. T
Best Project Award under SDG-6 for “DRUG DEVELOPMENT USING MICROALGAE FOR HINDRANCE OF CANCER CELLS” ; National Level best Innovative project Award for “BIOENGINEERED SKIN SUBSTITUTE FOR BURN INJURYAND SKIN REJUVENATION”; Real time project Innovation award for “NANO-SENSOR BASED REAL TIME DISINFECTANT DETECTION” ; Best Real time product Award for “BIOSENSORS FOR MILK ADULTERANT DETECTION” ; and EMERGING ENTREPRENEURSHIP AWARD
Creating a multi-layered targeted drug delivery system for atherosclerosis involves interdisciplinary research. Key areas include understanding atherosclerosis and identifying specific biomarkers, selecting therapeutic agents and studying combination therapies, and designing biocompatible nanocarriers for controlled drug release. Research on targeting mechanisms and ligand-receptor interactions is crucial. Developing multi-layered systems with functionalized layers for precise targeting and drug release is essential. Imaging and monitoring techniques to track drug delivery and release in real-time are also vital.
